MA-VERISTAT
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Art Collective teamLab to Open New Museum, teamLab Biovortex Kyoto on October 7, 20257.8.2025 08:00:00 CEST | Press release
Unveiling 7 artworks, including pieces never before exhibited in Japan. Tickets on Sale now teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025. This will be teamLab's largest museum in Japan, spanning over 10,000 square meters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806347101/en/ Even if individual elements are separated in space and time, when a structural order appears among them, the elements transcend space and time and form a single entity. Despite significant changes in shape or size on the surface, or even if all of the elements are replaced, the single existence will be maintained. This spatiotemporal existence is part of the whole, it appears from the whole, and is returned to it. It is a living universe - a biocosmos. (teamLab, Morphing Continuum © teamLab) In preparation for th
Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions7.8.2025 07:13:00 CEST | Press release
2Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806235547/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Allianz achieves strong growth and record operating profitTotal business volume rises 8.01 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders’ core net income increases 7.1 percent 6M 2025 Excellent performance across our businesses and record operating profitTotal business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-
New pulp mill boosts Suzano's sales and revenue in the second quarter of 20257.8.2025 04:17:00 CEST | Press release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24. The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. Beto
Graanul - Update on the Consent Solicitation and Scheme Solicitation6.8.2025 22:22:00 CEST | Press release
Graanul: Update on the Consent Solicitation and Scheme Solicitation relating to: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and together with its subsidiaries, “Graanul”
Statement by Aviator LLC6.8.2025 16:18:00 CEST | Press release
Company successfully initiates proceedings following Georgian court victories; UK injunction preserves status quo pending trial Aviator LLC today issued a statement clarifying the nature and scope of a recent UK court ruling following public statements made by SPRIBE OU regarding interim injunction proceedings. According to Nikoloz Gogilidze, legal representative for Aviator LLC, the recent court order was an interim injunction with limited scope and commercial impact. Gogilidze highlights the key points of the proceedings, which appear to have been mischaracterized in some media reports. Nature of the Court Order: The ruling represents an interim injunction granted at a preliminary procedural stage, not a final determination on the merits of the underlying dispute. Such orders are designed to maintain the status quo pending full trial proceedings. Commercial Impact: The injunction has no practical effect as neither Aviator LLC nor its IP rights licensee had any existing plans to enter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom